All News
The EULAR 2015 Report - Wednesday
EULAR 2015 started the afternoon of Wednesday June 10th.
Read ArticleRheumatic Manifestations of Chikungunya Virus
Chikungunya is a new viral cause of fever and arthritis, especially in endemic areas like the caribbean. The chikungunya epidemic has grown significantly in the Western hemisphere with a total of 1,247,000 cases and 183 fatalities since
Read ArticleTofacitinib Equal to Etanercept in Psoriasis, but only at 10 mg bid Dose
A 12-week, phase III, non-inferiority, randomized clinical trial of tofacitinib, etanercept or placebo was conducted in 1106 patients with plaque psoriasis.
Read ArticleAmgen Halts Development of Brodalumab
IL-17 inhibitors are being developed for treatment of psoriasis, psoriatic arthritis and axial spondyloarthritis. Broadalumab has been in phase II & III trials and been developed by a partnership between Amgen and Astra-Zeneca.
Read ArticleAdalimumab Gets FDA Orphan Drug Status for Use in Hidradenitis Suppurativa
The FDA has granted adalimumab (Humira) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease).
Read ArticleThe National Prevalence of HLA-B27 in the U.S.
HLA-B27 is found 6.1% of the US population, but with is seen in >90% patients with ankylosing spondylitis. HLA-B27 increases risk of spondylitis, uveitis and heart block. [Image credit: "HLA-B*2705" by Pdeitiker - Own work. Licensed under Public Domain via Wikimedia Commons]
Read Article
Patient perspectives in the management of psoriasis and PsA
A psoriasis population survey finds psoriasis or psoriatic arthritis in 1.4%-3.3% of North American and European households. Many (27-53%) rated their disease as “severe”.
Read ArticleAS vs. SpA Responses with Combination Treatment
Patients in a large Swedish registry with ankylosing spondylitis (AS) and spondyloarthritis (SpA) who started a TNF inhibitor were followed for comedication use and TNF inhibitor survival.
Read ArticleThe Prevalence of Ankylosing Spondylitis
A retrospective study of the national register in Sweden identified a total of 11,030 cases with an ankylosing spondylitis (AS) diagnosis (as of 2009) were identified in the National Patient Register, giving a point prevalence of 0.18% in 2009. Men had a higher prevalence of ankylo
Read ArticlePsoriatic Arthritis Has a New FDA Approved DMARD - Apremilast
In March 2014 the FDA approved apremilast (Otezla) for use in psoriatic arthritis based on three large"Palace" trials involving 1493 psoriatic arthritis patients. This ACR Hotline reviews the drugs use, efficacy, and toxicity.
Read Article